ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 30 2025
0mins
Source: Globenewswire
Alzheimer's Disease Treatment Development: ProMIS Neurosciences has initiated a Phase 1b clinical trial for its lead antibody candidate PMN310, targeting toxic amyloid-beta oligomers in Alzheimer's disease, with interim results expected in 2026. The company aims to validate PMN310 as a potential best-in-class treatment through robust clinical data and biomarker insights.
Financial Performance and Pipeline Expansion: In 2024, ProMIS reported a net income of $2.8 million, attributed to gains from financial instruments, while also advancing its research programs in ALS and Parkinson’s disease, alongside expanding its intellectual property portfolio with new patents related to its therapeutic candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
